TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04210050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.
Description: In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring.
Study: NCT01049516

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Therapy
Description: 10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
Study: NCT04278937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Tablets
Description: one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
Study: NCT04210050

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Arterial blood gas (ABG) and serum bicarbonate level
Description: Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas (ABG) and serum bicarbonate level
Description: Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Overnight home oximetry and transcutaneous CO2 monitoring
Description: will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
Study: NCT00160199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROMETRIUM® 300 mg
Description: 300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROMETRIUM® 400 mg
Description: 400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
Study: NCT03452826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy according to the result of mPCR (device)
Description: * Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms.
Study: NCT00689000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797 (tosedostat): Aminopeptidase inhibitor
Description: Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study
Study: NCT02751034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuramis® Deep Lidocaine
Description: HA filler
Study: NCT04210050

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Overnight home oximetry and transcutaneous CO2 monitoring
Description: will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
Study: NCT03918460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANEUFIX
Description: ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
Study: NCT01687972

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Insorb absorbable staples
Description: Placement of Insorb absorbable staples at cesarean section

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable sutures
Description: placement of absorbable sutures at cesarean section
Study: NCT01270191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
Study: NCT02751034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane® PERLANE-L
Description: HA filler
Study: NCT02327936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Administer medication to patients with overactive bladder
Study: NCT00004474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: Given via IV over 4 hours
Study: NCT01270191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-N
Description: The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
Study: NCT02876757

Intervention type: DRUG
Intervention: 5ARI
Description: Exposure to finasteride/dutasteride
Study: NCT03492086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with capsules containing rosemary and alkylglycerol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplementation with control capsules
Study: NCT00683345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
Study: NCT02327936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin XL
Description: Administer medication to patients with overactive bladder
Study: NCT04254016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIBISTEVER1
Description: During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
Study: NCT02436408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Study: NCT02782325

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active FMT, then open label FMT
Description: Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
Study: NCT00683345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.67 ml daily subcutaneously as placebo drug.
Study: NCT01017796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and ascorbic acid
Description: 1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine and ascorbic acid
Description: 1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
Study: NCT00880789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/AdV specific T cells
Description: CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
Study: NCT02782325

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT, then open label FMT
Description: Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
Study: NCT01115335

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal male circumcision
Description: Circumcision performed on a male infant within the first month of life, using one of 3 devices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal male circumcision
Description: Circumcision performed on a male infant within the first month of life, using one of 3 devices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal male circumcision
Description: Circumcision performed on a male infant within the first month of life, using one of 3 devices
Study: NCT04184128

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
Study: NCT01304810

Intervention type: BIOLOGICAL
Intervention: NicVAX vaccine
Description: Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.

Intervention type: BIOLOGICAL
Intervention: Placebo
Description: Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
Study: NCT02165462

Intervention type: OTHER
Intervention: Patients with haemophilia
Description: Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
Study: NCT04416607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menotropins
Description: Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
Study: NCT02916225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Moderate Continuous Training
Description: The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
Study: NCT02989844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
Study: NCT01312389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-L/Montanide ISA 51 VG
Description: All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-L/Montanide ISA 51 VG
Description: All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-L/Montanide ISA 51 VG
Description: All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampligen
Description: All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampligen
Description: All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
Study: NCT00004474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given via IV over 60 minutes on Days -5 to -2
Study: NCT01312389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
Study: NCT01945736

Intervention type: DRUG
Intervention: Methadone
Description: To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.

Intervention type: DRUG
Intervention: Methadone
Description: To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.

Intervention type: DRUG
Intervention: Methadone
Description: To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
Study: NCT02035956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC MUTANOME, RBL001/RBL002
Description: Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
Study: NCT00004474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given via IV over 60 minutes on Days -5 to -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Given on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Given on Day 0
Study: NCT01107119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated care pathway
Description: communication and follow-up program for integrated care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT04041206

Intervention type: DEVICE
Intervention: Laser doppler
Description: Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian

Intervention type: DEVICE
Intervention: Laser doppler
Description: Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian
Study: NCT02564861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS 1971a is supplied as a powder or crystals and will be given as an oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS 1971a is supplied as a powder or crystals and will be given as an oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS 1971a is supplied as a powder or crystals and will be given as an oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching DS-1971a suspension
Study: NCT01012921

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: barrier membrane
Description: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: barrier membrane
Description: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MembraGel
Description: Device application at surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide® membrane
Description: Device application at surgery
Study: NCT01666639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Medical Rehabilitation plus behavioral exercise therapy
Description: The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Behavioral Medical Rehabilitation
Description: The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each.
Study: NCT03183050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question Prompt List
Description: Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.